Saccharomyces boulardii's efficiency on hyperbilirubinemia

Phase 3

• Conditions: eonatal hyperbilirubinemia.; Neonatal jaundice from breast milk inhibitor; P 59.3

• Registration Number: IRCT2012123010279N2
• Lead Sponsor: Health Ministry Drug and Pharmacy General Management

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

1.Late preterm (34, not completed week – 36, completed week) gestational weeks ) and term (= 37 gestational weeks) neonates
2. Newborns who need phototherapy for neonatal hyperbilirubinemia
3. Newborns who were 0-1 month old.

Exclusion criteria:
1. Newborns who have congenital anomalies
2. Newborns who need intense phototherapy
3.Direct coombs positive ABO/Rh incompatability
4.Neonates who have sepsis/pneumonia during phototherapy
5.Neonates with hypothyroidism
6.Neonates who have gastrointestinal obstruction
7.Neonates with asphyxia
8.Contraindication of peroral feeding

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Phototherapy duration. Timepoint: Starts at the same time with the intervention. Method of measurement: Patients' medical records.;Maximum bilirubinemia level. Timepoint: Starts at the same time with the intervention. Method of measurement: Patients' laboratory records.